PMID- 38201527 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240114 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 16 IP - 1 DP - 2023 Dec 24 TI - Recurrence-Free Survival and Disease-Specific Survival in Patients with Pancreatic Neuroendocrine Neoplasms: A Single-Center Retrospective Study of 413 Patients. LID - 10.3390/cancers16010100 [doi] LID - 100 AB - INTRODUCTION: The prognosis and impact of different prognostic factors in pancreatic neuroendocrine neoplasms (pNEN) remain controversial. AIM: To investigate prognostic factors for recurrence-free survival and disease-specific survival in patients with pNEN, divided into three groups: patients undergoing surveillance (tumor size < 2 cm, group 1), patients followed after curative-intended surgery (group 2), and patients with unresectable disease or residual tumors after resection (group 3). METHOD: A single-center retrospective study including consecutive patients over a 20-year period. Multivariate Cox regression analyses were performed to identify risk factors. RESULTS: 413 patients were included, with a mean (SD) age of 62 +/- 14 years. In group 1 (n = 51), median (IQR) follow-up was 29 (21-34) months, and tumor size was 1.0 (0.8-1.4) cm. One progressed and had a tumor resection. In group 2 (n = 165), follow-up 59 (31-102) months, median tumor size 2 (1.2-3.4) cm, median Ki-67 index 5 (3-10)%, the 5-year recurrence rate was 21%. Tumor size (p < 0.001), Ki-67 index (p = 0.02), and location in the pancreatic head (p < 0.001) were independent risk factors. In group 3 (n = 197), follow-up 19 (6-46) months, median tumor size 4.2 (2.6-7.0) cm, Ki-67 index 17 (9-64)%, the median disease-specific survival was 22 (6-75) months-99 in NET G1; 54 in NET G2; 14 in NET G3; and 6 months in neuroendocrine carcinomas (NEC). Age (p = 0.029), plasma chromogranin A (p = 0.014), and proliferation, expressed by grade (p = 0.001) and Ki-67 index (p < 0.001), were risk factors. CONCLUSION: Growth in pNET < 2 cm requiring surgery was observed in 1/51. Tumor size, Ki-67 index, and location in the head were prognostic factors for disease recurrence, while age, plasma chromogranin A, and proliferation predicted mortality in patients with unresectable disease or residual tumors after resection. FAU - Moller, Stine AU - Moller S AD - ENETS Center of Excellence, Copenhagen University Hospital-Rigshospitalet, 2100 Copenhagen, Denmark. AD - Department of Endocrinology and Metabolism 7562, Copenhagen University Hospital-Rigshospitalet, 2100 Copenhagen, Denmark. FAU - Langer, Seppo W AU - Langer SW AUID- ORCID: 0000-0001-9732-9192 AD - ENETS Center of Excellence, Copenhagen University Hospital-Rigshospitalet, 2100 Copenhagen, Denmark. AD - Department of Oncology, Copenhagen University Hospital-Rigshospitalet, 2100 Copenhagen, Denmark. AD - Department of Clinical Medicine, University of Copenhagen, 1172 Copenhagen, Denmark. FAU - Slott, Cecilie AU - Slott C AD - ENETS Center of Excellence, Copenhagen University Hospital-Rigshospitalet, 2100 Copenhagen, Denmark. AD - Department of Endocrinology and Metabolism 7562, Copenhagen University Hospital-Rigshospitalet, 2100 Copenhagen, Denmark. FAU - Krogh, Jesper AU - Krogh J AD - ENETS Center of Excellence, Copenhagen University Hospital-Rigshospitalet, 2100 Copenhagen, Denmark. AD - Department of Endocrinology and Metabolism 7562, Copenhagen University Hospital-Rigshospitalet, 2100 Copenhagen, Denmark. AD - Department of Clinical Medicine, University of Copenhagen, 1172 Copenhagen, Denmark. FAU - Hansen, Carsten Palnaes AU - Hansen CP AUID- ORCID: 0000-0002-9256-2240 AD - ENETS Center of Excellence, Copenhagen University Hospital-Rigshospitalet, 2100 Copenhagen, Denmark. AD - Department of Surgery and Transplantation, Copenhagen University Hospital-Rigshospitalet, 2100 Copenhagen, Denmark. FAU - Kjaer, Andreas AU - Kjaer A AUID- ORCID: 0000-0002-2706-5547 AD - ENETS Center of Excellence, Copenhagen University Hospital-Rigshospitalet, 2100 Copenhagen, Denmark. AD - Department of Clinical Physiology and Nuclear Medicine & Cluster for Molecular Imaging, Copenhagen University Hospital-Rigshospitalet, 2100 Copenhagen, Denmark. AD - Department of Biomedical Sciences, University of Copenhagen, 1172 Copenhagen, Denmark. FAU - Holmager, Pernille AU - Holmager P AUID- ORCID: 0000-0002-2133-5980 AD - ENETS Center of Excellence, Copenhagen University Hospital-Rigshospitalet, 2100 Copenhagen, Denmark. AD - Department of Endocrinology and Metabolism 7562, Copenhagen University Hospital-Rigshospitalet, 2100 Copenhagen, Denmark. FAU - Klose, Marianne AU - Klose M AD - ENETS Center of Excellence, Copenhagen University Hospital-Rigshospitalet, 2100 Copenhagen, Denmark. AD - Department of Endocrinology and Metabolism 7562, Copenhagen University Hospital-Rigshospitalet, 2100 Copenhagen, Denmark. FAU - Garbyal, Rajendra Singh AU - Garbyal RS AD - ENETS Center of Excellence, Copenhagen University Hospital-Rigshospitalet, 2100 Copenhagen, Denmark. AD - Department of Pathology, Copenhagen University Hospital-Rigshospitalet, 2100 Copenhagen, Denmark. FAU - Knigge, Ulrich AU - Knigge U AD - ENETS Center of Excellence, Copenhagen University Hospital-Rigshospitalet, 2100 Copenhagen, Denmark. AD - Department of Endocrinology and Metabolism 7562, Copenhagen University Hospital-Rigshospitalet, 2100 Copenhagen, Denmark. AD - Department of Surgery and Transplantation, Copenhagen University Hospital-Rigshospitalet, 2100 Copenhagen, Denmark. FAU - Andreassen, Mikkel AU - Andreassen M AUID- ORCID: 0000-0002-1656-3516 AD - ENETS Center of Excellence, Copenhagen University Hospital-Rigshospitalet, 2100 Copenhagen, Denmark. AD - Department of Endocrinology and Metabolism 7562, Copenhagen University Hospital-Rigshospitalet, 2100 Copenhagen, Denmark. AD - Department of Clinical Medicine, University of Copenhagen, 1172 Copenhagen, Denmark. LA - eng PT - Journal Article DEP - 20231224 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC10777990 OTO - NOTNLM OT - clinical presentation OT - incidence OT - pancreatic neuroendocrine neoplasms OT - prognosis COIS- All authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2024/01/11 07:42 MHDA- 2024/01/11 07:43 PMCR- 2023/12/24 CRDT- 2024/01/11 01:06 PHST- 2023/10/27 00:00 [received] PHST- 2023/12/18 00:00 [revised] PHST- 2023/12/19 00:00 [accepted] PHST- 2024/01/11 07:43 [medline] PHST- 2024/01/11 07:42 [pubmed] PHST- 2024/01/11 01:06 [entrez] PHST- 2023/12/24 00:00 [pmc-release] AID - cancers16010100 [pii] AID - cancers-16-00100 [pii] AID - 10.3390/cancers16010100 [doi] PST - epublish SO - Cancers (Basel). 2023 Dec 24;16(1):100. doi: 10.3390/cancers16010100.